On January 22, 2026, Vishwas Seshadri, the Chief Executive Officer of Abeona Therapeutics Inc. (NASDAQ: ABEO), completed a transaction involving the sale of 69,832 common shares. These shares were sold at prices spanning from $5.33 to $5.38 each, culminating in a total transaction value of $372,267. Documentation of this sale was filed with the Securities and Exchange Commission through a Form 4 filing.
The purpose of this equity liquidation was to fulfill tax obligations associated with the vesting of restricted stock awards. Post-transaction, Seshadri retains direct ownership of 1,460,408 shares in Abeona Therapeutics.
In tandem with this insider activity, Abeona Therapeutics announced a robust financial performance in its third-quarter 2025 earnings report. The company reported earnings per share (EPS) of negative 10 cents, a notable outperformance compared with analyst estimates that projected an EPS of negative 27 cents. This 62.96% upside was attributed to disciplined cost management and encouraging progress with product development efforts.
From an equity analyst standpoint, Cantor Fitzgerald has sustained an Overweight rating on Abeona Therapeutics shares and set a price target of $28.00, indicating bullish sentiment tied to the firm's focus on therapies addressing rare genetic diseases. Conversely, Stifel updated its price target downward to $19.00 from $20.00, citing a temporary postponement in the commercial launch of Abeona's gene therapy product Zevaskyn due to issues uncovered in a sterility assay.
Furthermore, Abeona has expanded clinical accessibility for its FDA-cleared gene therapy, ZEVASKYN, designed to treat recessive dystrophic epidermolysis bullosa (RDEB). The University of Texas Medical Branch has been recently activated as a new treatment center, underscoring Abeona's ongoing efforts to enhance patient reach for this rare disease therapy.
Leadership changes also feature prominently, with the appointment of Mohamad Tabrizi as Chief Business Officer. Bringing expertise from the venture capital domain, Tabrizi's role is expected to bolster Abeona’s corporate strategy and business development capabilities as it advances its gene therapy pipeline.
Collectively, these insider transactions, financial results, operational expansions, and leadership appointments illustrate Abeona Therapeutics’ pursuit of growth opportunities within the gene therapy and rare disease treatment arena.